Updating results

528 results

Sort: Relevance | Date

Tagraxofusp for treating blastic plasmacytoid dendritic cell neoplasm ID1556

In development [GID-TA10482] Expected publication date: 24 March 2021

Technology appraisal guidance In development

Atezolizumab with gemcitabine and carboplatin for treating metastatic urothelial bladder cancer [ID1206]

In development [GID-TA10202] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab for previously treated squamous non-small-cell lung cancer (CDF Review TA483) [ID1559]

In development [GID-TA10516] Expected publication date: TBC

Technology appraisal guidance In development

Osimertinib for untreated EGFR-positive non-small-cell lung cancer [ID1302]

In development [GID-TA10255] Expected publication date: 19 February 2020

Technology appraisal guidance In development

Pembrolizumab in combination for untreated, locally advanced or metastatic, triple negative breast cancer ID1546

In development [GID-TA10417] Expected publication date: 21 April 2021

Technology appraisal guidance In development

Pembrolizumab with pemetrexed and platinum-based chemotherapy for untreated non-small-cell lung cancer (CDF Review of TA557) [ID1584]

In development [GID-TA10529] Expected publication date: 24 June 2020

Technology appraisal guidance In development

Cannabidiol for adjuvant treatment of seizures associated with Dravet syndrome [ID1211]

In development [GID-TA10274] Expected publication date: 18 December 2019

Technology appraisal guidance In development

Cannabidiol for adjuvant treatment of seizures associated with Lennox-Gastaut syndrome [ID1308]

In development [GID-TA10410] Expected publication date: 18 December 2019

Technology appraisal guidance In development

Trifluridine–tipiracil for treating metastatic gastric or gastro-oesophageal junction cancer after 2 or more therapies [ID1507]

In development [GID-TA10456] Expected publication date: TBC

Technology appraisal guidance In development

Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia [ID1402]

In development [GID-TA10328] Expected publication date: TBC

Technology appraisal guidance In development

Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis [ID1521]

In development [GID-TA10471] Expected publication date: 04 March 2020

Technology appraisal guidance In development

Solriamfetol for treating excessive sleepiness caused by obstructive sleep apnoea [ID1499]

In development [GID-TA10430] Expected publication date: 27 January 2021

Technology appraisal guidance In development

Liraglutide for managing overweight and obesity [ID740]

In development [GID-TA10388] Expected publication date: 04 March 2020

Technology appraisal guidance In development

Ustekinumab for treating moderately to severely active ulcerative colitis [ID1511]

In development [GID-TA10434] Expected publication date: 04 March 2020

Technology appraisal guidance In development

Siponimod for treating secondary progressive multiple sclerosis [ID1304]

In development [GID-TA10436] Expected publication date: 27 May 2020

Technology appraisal guidance In development

Palbociclib in combination with fulvestrant for treating advanced, hormone-receptor positive, HER2-negative breast cancer after endocrine therapy [ID916]

In development [GID-TA10095] Expected publication date: 15 January 2020

Technology appraisal guidance In development

Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (including review of TA381) [ID1296]

In development [GID-TA10303] Expected publication date: 15 January 2020

Technology appraisal guidance In development

Multiple myeloma - lenalidomide (maintenance, post autologous stem cell transplantation) [ID475]

In development [GID-TAG430] Expected publication date: 28 October 2020

Technology appraisal guidance In development

Brigatinib for untreated ALK-positive metastatic non-small-cell lung cancer ID1468

In development [GID-TA10351] Expected publication date: 27 January 2021

Technology appraisal guidance In development

Talazoparib for treating BRCA 1 or 2 mutated advanced breast cancer after prior chemotherapy (ID1342)

In development [GID-TA10366] Expected publication date: TBC

Technology appraisal guidance In development

Pitolisant hydrochloride for treating obstructive sleep apnoea ID1065

In development [GID-TA10385] Expected publication date: 27 January 2021

Technology appraisal guidance In development

Pembrolizumab with etoposide and a platinum-based compound for untreated extensive-stage small-cell lung cancer ID1509

In development [GID-TA10413] Expected publication date: 16 December 2020

Technology appraisal guidance In development

Pembrolizumab with platinum-based chemotherapy and radiation for treating unresectable locally advanced squamous cell carcinoma of the head and neck [ID1667]

In development [GID-TA10567] Expected publication date: 24 November 2021

Technology appraisal guidance In development

Xpert MTB/RIF assay for the detection of active pulmonary tuberculosis and multi-drug resistant tuberculosis

In development [GID-DT9] Expected publication date: TBC

Diagnostics guidance In development

KRAS mutation testing of tumours in adults with metastatic colorectal cancer (discontinued)

In development [GID-DT14] Expected publication date: TBC

Diagnostics guidance In development

Housing: planning to improve health and wellbeing

In development [GID-NG10053] Expected publication date: TBC

NICE guideline In development

Diagnostic services

In development [GID-CGWAVE0773] Expected publication date: TBC

NICE guideline In development

Assessment, referral and management of Adrenal dysfunction

In development [GID-NG10052] Expected publication date: TBC

NICE guideline In development

Personal, social, health and economic education focusing on sex and relationships and alcohol education

In development [GID-PHG0] Expected publication date: TBC

NICE guideline In development

Workplace health - older employees

In development [GID-PHG59] Expected publication date: 24 March 2016

NICE guideline In development

Workplace health for employees with disabilities and long-term conditions

In development [GID-PHG58] Expected publication date: TBC

NICE guideline In development

Reducing the mortality and morbidity for healthcare associated infections

In development [GID-NG10059] Expected publication date: TBC

NICE guideline In development

Hernia

In development [GID-CGWAVE0771] Expected publication date: TBC

NICE guideline In development

Sapropterin for treating phenylketonuria [ID1475]

In development [GID-TA10378] Expected publication date: TBC

Technology appraisal guidance In development

Tezacaftor and ivacaftor combination therapy for treating cystic fibrosis with the F508del mutation [ID1303]

In development [GID-TA10277] Expected publication date: TBC

Technology appraisal guidance In development

Canakinumab for preventing cardiovascular events after myocardial infarction in people with raised high-sensitivity C-reactive protein (ID1362)

In development [GID-TA10337] Expected publication date: 19 February 2020

Technology appraisal guidance In development

Nivolumab with radiation therapy for untreated glioblastoma ID1562

In development [GID-TA10443] Expected publication date: TBC

Technology appraisal guidance In development

Ibrutinib combination therapy for untreated diffuse large B-cell lymphoma ID997

In development [GID-TA10382] Expected publication date: TBC

Technology appraisal guidance In development

Mepolizumab for treating eosinophilic granulomatosis with polyangiitis ID1186

In development [GID-TA10289] Expected publication date: TBC

Technology appraisal guidance In development

Leukaemia (acute myeloid, relapsed, refractory) - vosaroxin [ID746]

In development [GID-TA10070] Expected publication date: TBC

Technology appraisal guidance In development

Idelalisib with bendamustine and rituximab for previously treated chronic lymphocytic leukaemia [ID839]

In development [GID-TA10109] Expected publication date: TBC

Technology appraisal guidance In development

Renal cell carcinoma - sunitinib [ID1076]

In development [GID-TA10166] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab for previously treated gastric or gastro-oesophageal junction cancer [ID1118]

In development [GID-TA10151] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab for treating recurrent glioblastoma [ID998]

In development [GID-TA10126] Expected publication date: TBC

Technology appraisal guidance In development

Pembrolizumab for previously treated metastatic colorectal cancer that has high microsatellite instability or mismatch repair deficiency [ID1071]

In development [GID-TA10110] Expected publication date: TBC

Technology appraisal guidance In development

Breast cancer (metastatic) -trastuzumab (as monotherapy and in combination with a taxane) [ID345]

In development [GID-TAG417] Expected publication date: TBC

Technology appraisal guidance In development

Bone metastases (hormone refractory prostate cancer) - denosumab [ID405]

In development [GID-TAG300] Expected publication date: TBC

Technology appraisal guidance In development

Hepatitis C (genotype 1, chronic) - faldaprevir [ID670]

In development [GID-TAG456] Expected publication date: TBC

Technology appraisal guidance In development